Up-regulated Immunoreactivity for the Rpb3 antigens was observed in 16.13% (5/31) of the patients with Stage I HCC tissues, 36.67% (33/90) of the patients with Stage II HCC tissues, 54.72% (58/106) the patients with Stage III HCC tissues, and 72.63% (69/95) the patients with Stage IV HCC tissues. This evidence concerns the gene POLR2C and hepatocellular carcinoma.